September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Effects of Aflibercept on Patients with Polypoidal Choroidal Vasculopathy: One-year results of VAULT Study
Author Affiliations & Notes
  • Hyun Woong Kim
    Department of ophthalmology, Busan Paik hospital, Inje University, Busan, Korea (the Republic of)
  • Joo Eun Lee
    Department of ophthalmology, Haeundae Paik hospital, Inje University, Busan, Korea (the Republic of)
  • Jae Pil Shin
    Department of Ophthalmology, Kyungpook National University Hospital, Daegu, Korea (the Republic of)
  • Woohyok Chang
    Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Korea (the Republic of)
  • Yu Cheol Kim
    Department of Ophthalmology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea (the Republic of)
  • Sang Joon Lee
    Department of Ophthalmology, Kosin University College of Medicine, Busan, Korea (the Republic of)
  • In Young Chung
    Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Korea (the Republic of)
  • Ji Eun E Lee
    Department of Ophthalmology, Pusan National University Hospital, Busan, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Hyun Woong Kim, Allergan (S), Bayer (C), Norvatis (C); Joo Eun Lee, Alcon (R), Allergan (C), Bayer (R), Norvatis (R); Jae Pil Shin, None; Woohyok Chang, Allegan (C), Bayer (C), Norvatis (R); Yu Cheol Kim, None; Sang Joon Lee, None; In Young Chung, None; Ji Eun Lee, Allergan (C), Bayer (F), Bayer (C), Norvatis (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 513. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hyun Woong Kim, Joo Eun Lee, Jae Pil Shin, Woohyok Chang, Yu Cheol Kim, Sang Joon Lee, In Young Chung, Ji Eun E Lee; Effects of Aflibercept on Patients with Polypoidal Choroidal Vasculopathy: One-year results of VAULT Study. Invest. Ophthalmol. Vis. Sci. 2016;57(12):513.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To investigate efficacy of aflibercept for treatment naïve PCV.

Methods : A prospective, single-arm, interventional case series. Three doses of initial monthly intravitreal aflibercept 2.0 mg injections were followed by every two month maintenance injections. At every visit, best-corrected visual acuity (BCVA) measurement using ETDRS chart, and spectral domain optical coherence tomography (OCT) were performed before the injections. Fluorescein angiography (FA) and Indocyanine green angiography (ICGA ) were obtained at baseline, month 3, and month 12. Primary outcome measure was the ratio of patients who maintained visual acuity without losing 15 ETDRS letters or more at month 12. Changes in ETDRS visual acuity, macular appearance on OCT, and polypoidal lesions on ICGA were also evaluated.

Results : From 48 patients initially enrolled, 40 patients finished complete follow up and were included in the final analysis. Mean age was 67.0 years old (range; 44-84). Thirty five eyes (87.5%) did not lose visual acuity more than 15 letters at month 12. Mean ETDRS letter score showed significant improvement from 55.1 at baseline to 64.2 at month 12 (9.0 letters gain, p<0.001). Mean central macular thickness measured by OCT changed significantly from 365.2μm at baseline 253.6at month 12 (p<0.001). Complete dry-up of macular was seen in 32 (76.2%), 27 (64.3%), and 24 (60.0%) eyes at month 3, 6, and 12, respectively. Reappearance or increase of fluid was noted in 14 at month 6, and 16 patients at month 12. Complete polyp regression was achieved in 27 (64.3%) and 26 eyes (66.7%), at month 3, and 12, respectively.

Conclusions : Functional and anatomical outcomes were favorable after aflibercept intravitreal injection for PCV patients. However, fluid reaccumulation and new polyp formation was seen in one-third of the patients after extending treatment interval. Bimonthly injections may be suboptimal and more frequent injections are needed to maintain stable condition achieved by initial monthly injections in some of PCV patients.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.




This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.